Viracta Therapeutics
2007
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Series D
LATEST DEAL TYPE
$16.8M
LATEST DEAL AMOUNT
10
INVESTORS
Description
Operator of a clinical-stage drug development company intended to develop medicines to treat virus-associated cancers. The company's platform focuses on advancing new therapies to address a broad range of cancers and virus-associated diseases, enabling patients to treat cancers associated with the Epstein-Barr Virus (EBV) and other serious diseases.
Website
Formerly Known As
Hemagenex Pharmaceuticals, HemaQuest Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
- 2533 South Coast Highway 101
- Suite 210
- Cardiff, CA 92007
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Viracta Therapeutics’s full profile, request a free trial.
Viracta Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series D) | 05-Nov-2019 | $16.8M | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 4. Later Stage VC (Series C) | 12-Feb-2019 | 000.00 | 000.00 | Completed | Product Development | |
| 3. Later Stage VC (Series B) | 04-Apr-2017 | 000.00 | 000.00 | 000.00 | Completed | Product Development |
| 2. Later Stage VC (Series B) | 08-Jun-2012 | $29M | $49.3M | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 01-Nov-2007 | $20.3M | $20.3M | 000.00 | Completed | Startup |
Viracta Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series C | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 23,549,212 | $0.000100 | 8% | $0.71 | $0.71 | 1x | $0.71 | 21.51% |
| Series A1 | 34,461,663 | $0.000100 | 8% | $0.4 | $0.4 | 1x | $0.32 | 37.82% |
Viracta Therapeutics Competitors (31)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Affimed Therapeutics | Formerly VC-backed | Heidelberg, Germany | 000 | 00000 | 00000000000 | 00000 |
| 00000000000 | Angel-Backed | Culver City, CA | 00000 | 000000000000 | 00000 | |
| 00000000 | Venture Capital-Backed | Tübingen, Germany | 000 | 00000 | 00000000000 | 00000 |
| 00000000 | Venture Capital-Backed | Madison, WI | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Dallas, TX | 00 | 00000 | 000000&0 | 00000 |
Viracta Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Taiwania Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Salubris | Corporation | Minority | 000 0000 | 000000 0 | ||
| VI Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| NantKwest | Corporation | Minority | 000 0000 | 000000 0 | ||
| Wicklow Capital | Family Office | Minority | 000 0000 | 000000 0 |
Viracta Therapeutics Executive Team (5)
Viracta Therapeutics Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Barry Simon MD | NantKwest | Board Member | 000 0000 | |
| Douglas Faller MD | Viracta Therapeutics | Chairman of the Scientific Advisory Board & Scientific Founder | 000 0000 | |
| Ivor Royston MD | Viracta Therapeutics | President, Chief Executive Officer & Board Member | 000 0000 | |
| James Woody Ph.D | Latterell Venture Partners | Board Member | 000 0000 | |
| Michael Huang | Taiwania Capital | Board Member | 000 0000 |